Needham analyst Ami Fadia upgraded Neurocrine (NBIX) to Buy from Hold with a $138 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine upgraded to Outperform at RBC Capital following pullback
- Neurocrine upgraded to Outperform from Sector Perform at RBC Capital
- Neurocrine price target lowered to $155 from $163 at Guggenheim
- Neurocrine Biosciences Appoints Dr. Keswani as CMO
- Neurocrine names Dr. Sanjay Keswani as Chief Medical Officer